Mestinon (Pyridostigmine)

Pyridostigmine works by reversibly inhibiting the enzyme acetylcholinesterase at the neuromuscular junction. This inhibition prevents the breakdown of acetylcholine, allowing more of the neurotransmitter to remain available to stimulate nicotinic receptors, which improves the transmission of nerve signals to muscles.

The appropriate dose of Mestinon is individualized by a qualified prescriber based on the patient’s condition, severity, age, renal function and response to therapy. Dosage adjustments are made during treatment to achieve the desired clinical effect while minimizing side effects.

The safety of pyridostigmine in pregnancy and lactation has not been definitively established, and it is classified as pregnancy category unknown. Healthcare providers should weigh potential benefits against possible risks and consider alternative therapies when appropriate.

To order Mestinon, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Mestinon (pyridostigmine) is a symptomatic acetylcholinesterase inhibitor, whereas other options such as immunosuppressants, corticosteroids or monoclonal antibodies target the underlying immune response. Pyridostigmine provides rapid improvement in muscle strength but does not modify disease progression, making it complementary to disease‑modifying therapies.

Mestinon tablets should be stored at ambient temperature, below 25 °C, in the original container to protect them from moisture and light. Keeping the product in a dry, well‑sealed package helps maintain its stability and potency throughout its shelf life.

Mestinon is taken orally, usually in tablet form, with or without food as directed by the prescribing clinician. The tablets are swallowed whole with a glass of water, and the dosing schedule is adjusted based on the individual’s therapeutic response and tolerability.

The most serious risks include cholinergic crisis, which can cause severe muscle weakness, respiratory failure, and potentially life‑threatening complications. Other critical concerns are bronchospasm, marked bradycardia, cardiac arrhythmias and, in rare cases, seizures. Prompt medical attention is required if any of these symptoms arise.

Mestinon should be avoided in patients with known hypersensitivity to pyridostigmine or any excipients in the tablet. Caution is advised for individuals with mechanical intestinal obstruction, severe asthma, or uncontrolled cardiac conditions, as the drug may exacerbate these disorders.